Orthovita (VITA) Receives FDA 510(k) Clearance for CORTOSS
More News related to VITA
- Orthovita to Present at the Piper Jaffray 21st Annual Health Care Conference
- Orthovita to Participate in the Lazard Capital Markets 6th Annual Healthcare Conference
- Orthovita Reports 2009 Third Quarter Financial Results
- Orthovita to Host Investor Breakfast on Wednesday, November 11, 2009 in San Francisco, CA
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
More News related to FDA
- Deutsche Bank Starts Coverage on Utilities Stocks: CMS, AEP, EIX, ITC, PSEG at Buy
- Keefe, Bruyette and Woods Initiates Coverage of Taubman Centers (TCO) with an Outperform
- Keefe, Bruyette and Woods Initiates Coverage of Simon Property Group (SPG) with an Outperform
- Keefe, Bruyette and Woods Initiates Coverage of Tanger Factory Outlet Centers (SKT) with a Market Perform
- Keefe, Bruyette and Woods Initiates Coverage of Pennsylvania REIT (PEI) with a Market Perform
Orthovita, Inc. (NASDAQ: VITA) announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market CORTOSS Bone Augmentation Material for treatment of vertebral compression fractures.
CORTOSS is an injectable, bioactive composite that mimics the physiological properties of human cortical bone and is the first alternative to polymethylmethacrlyate (PMMA) cement that has been evaluated in a large-scale, multi-center, randomized, controlled clinical study and cleared in the United States for the treatment of vertebral compression fractures.
More from Release
Related Categories
FDAStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
